SGS has further demonstrated its commitment to the bio/pharmaceutical industry with new investment in a world-class bioanalytical testing laboratory in Shanghai, China, which had its opening ceremony on February 20, 2023.
We are delighted to announce the successful grand opening of the new SGS China bioanalysis center in Shanghai. The ceremony and subsequent drug R&D and quality forum took place on February 20, 2023 in the presence of:
- Gary Chambers, VP of Drug Development SGS Health Science (online presence)
- Dr. Hao Sandy, Managing Director of SGS China
- Dr. Lam Wai, Director of SGS Health Science in China
During the ceremony Dr. Wai commented: “The establishment of the China bioanalytical center will greatly improve capabilities in biological sample analysis and biopharmaceutical testing to meet clients’ needs – from preclinical studies to clinical trials, and filing INDs and NDAs efficiently and successfully.”
Drug Research & Development Forum
The ceremony was followed by a forum focusing on drug R&D and quality. The roundtable discussion focused on the “future development trend of pharmacovigilance and attention.”
Speakers who participated at the roundtable included:
- Dr. Chen Shaoxiong, Executive Chairman and Secretary-General of the Shanghai Biomedical Industry Association
- Dr. Huang Yi, Founder of Shanghai Tanshi Biology
- Rong Wang, Director of Pharmacovigilance Team, SGS China
- Shulin Zhong, Head of Immunochemistry, SGS China
- Feng Xiao, Head of Small Molecule Team, SGS China
Experts from the Biomedical Industry Association, the Adverse Drug Reaction Test Center for Drugs and Devices, the Shanghai Pudong Inspection and Testing Certification Industry Association attended the site, along with customer representatives.
Several guests focused on the pharmacovigilance system of full lifecycle supervision, highlighting the principle of “risk management, whole process control and social co-governance.” Everyone agreed that the establishment of a complete knowledge system around pharmacovigilance would improve the capacity of drug safety and ensure public health.
SGS bioanalytical lab
The growing energy and economic vitality of the Chinese market has driven our investment in the new, state-of-the-art bioanalytical laboratory in Shanghai.
The new laboratory is equipped with a range of highly specialized instruments such as Microplate Reader, MSD, Sciex Triple Quad 6500 LC-MS/MS, Molecular devices SpectraMax M5, MESO Sector S600 and Bio-rad bio-Plex 3D, as well as a Watson LIMS system and WinNonlin software for pharmacokinetics. In accordance with official OECD, FDA, NMPA, ICH and EMA guidelines, the bioanalytical center can design testing schemes, analyze biological samples and provide complete data analysis reports based on clients’ needs.
Gary Chambers, VP of Drug Development SGS Health Science, stated: “We are proud to step up our efforts in the Chinese local market, helping our customers bring their products to the market safely and efficiently.”
By leveraging our global network of leading experts, this bioanalytical laboratory will support the ongoing development of a safer and more interconnected world. SGS Health Science can provide bioanalytical testing for drug development from preclinical to early and late clinical phases.